Novo Nordisk Shares Outstanding 2010-2023 | NVO

Novo Nordisk shares outstanding history from 2010 to 2023. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Novo Nordisk shares outstanding for the quarter ending December 31, 2023 were 4.495B, a 1.1% decline year-over-year.
  • Novo Nordisk 2023 shares outstanding were 4.495B, a 1.1% decline from 2022.
  • Novo Nordisk 2022 shares outstanding were 4.545B, a 1.31% decline from 2021.
  • Novo Nordisk 2021 shares outstanding were 4.605B, a 1.6% decline from 2020.
Novo Nordisk Annual Shares Outstanding
(Millions of Shares)
2023 4,495
2022 4,545
2021 4,605
2020 4,680
2019 4,757
2018 4,849
2017 4,956
2016 5,069
2015 5,155
2014 5,260
2013 5,387
2012 5,517
2011 5,701
2010 5,855
2009 5,992
Novo Nordisk Quarterly Shares Outstanding
(Millions of Shares)
2023-12-31 4,495
2023-09-30 4,489
2023-06-30 4,503
2023-03-31 4,513
2022-12-31 4,545
2022-09-30 4,537
2022-06-30 4,545
2022-03-31 5,762
2021-12-31 4,605
2021-09-30 4,595
2021-06-30 4,610
2021-03-31 4,632
2020-12-31 4,680
2020-09-30 4,670
2020-06-30 4,691
2020-03-31 4,710
2019-12-31 4,757
2019-09-30 4,746
2019-06-30 4,767
2019-03-31 4,789
2018-12-31 4,849
2018-09-30 4,838
2018-06-30 4,862
2018-03-31 4,885
2017-12-31 4,956
2017-09-30 4,939
2017-06-30 4,968
2017-03-31 5,000
2016-12-31 5,069
2016-09-30 5,062
2016-06-30 5,082
2016-03-31 5,100
2015-12-31 5,155
2015-09-30 5,144
2015-06-30 5,168
2015-03-31 5,208
2014-12-31 5,260
2014-09-30 5,244
2014-06-30 5,275
2014-03-31 5,306
2013-12-31 5,387
2013-09-30 5,363
2013-06-30 5,405
2013-03-31 5,447
2012-12-31 5,517
2012-09-30 5,478
2012-06-30 5,524
2012-03-31 5,605
2011-12-31 5,619
2011-09-30 5,681
2011-06-30 5,738
2011-03-31 5,767
2010-12-31 5,775
2010-09-30 5,823
2010-06-30 5,889
2010-03-31 5,930
2009-12-31 5,952
2009-09-30 6,014
2009-06-30 6,030
2009-03-31 6,127
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $550.665B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $690.114B 114.92
Johnson & Johnson (JNJ) United States $356.431B 14.14
Merck (MRK) United States $318.604B 83.85
AbbVie (ABBV) United States $294.653B 14.98
AstraZeneca (AZN) United Kingdom $212.533B 18.83
Novartis AG (NVS) Switzerland $200.005B 13.86
Pfizer (PFE) United States $147.226B 14.21
Sanofi (SNY) $117.121B 10.55
Innoviva (INVA) United States $0.945B 6.67